These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 30188783)

  • 1. Low-Fat Abiraterone Food Effect Is of Great Consequence.
    Tannock IF
    J Clin Oncol; 2018 Oct; 36(30):3058-3059. PubMed ID: 30188783
    [No Abstract]   [Full Text] [Related]  

  • 2. Low-Fat Abiraterone Food Effect Is of Little Consequence.
    Kolesar JM; Liu GX
    J Clin Oncol; 2018 May; 36(14):1385-1386. PubMed ID: 29590006
    [No Abstract]   [Full Text] [Related]  

  • 3. Low-Dose Abiraterone With Food: Rebutting an Editorial.
    Szmulewitz RZ; Karrison T; Stadler WM; Ratain MJ
    J Clin Oncol; 2018 Oct; 36(30):3060-3061. PubMed ID: 30188785
    [No Abstract]   [Full Text] [Related]  

  • 4. Dose Reduction May Jeopardize Efficacy of Abiraterone Acetate.
    Woei-A-Jin FJSH; Van Nieuwenhuyse T; van Erp NP; Beuselinck B; Stroobants S; Moes DJAR; Osanto S; Spriet I
    J Clin Oncol; 2018 Oct; 36(30):3062-3064. PubMed ID: 30188790
    [No Abstract]   [Full Text] [Related]  

  • 5. Low-Dose Abiraterone Regimen: Drug Monitoring Might Be the Key.
    Tiako Meyo M; Alexandre J; Goldwasser F; Blanchet B
    J Clin Oncol; 2018 Oct; 36(30):3061-3062. PubMed ID: 30188788
    [No Abstract]   [Full Text] [Related]  

  • 6. There Is Now Compelling Evidence to Further Evaluate Lower Doses of Abiraterone Acetate in Men With Metastatic Prostate Cancer: It Should Be Safer, May Be as Effective and Less Expensive.
    Velho PI; Eisenberger MA
    J Clin Oncol; 2018 Oct; 36(30):3059-3060. PubMed ID: 30188787
    [No Abstract]   [Full Text] [Related]  

  • 7. Could Steroidal Abiraterone Metabolites Possibly Explain Abiraterone Withdrawal Syndrome?
    Caffo O; Sharifi N
    Eur Urol; 2016 Nov; 70(5):898-899. PubMed ID: 27339836
    [No Abstract]   [Full Text] [Related]  

  • 8. Prostate cancers that 'Wnt' respond to abiraterone.
    Linch M; Attard G
    Ann Oncol; 2018 Feb; 29(2):290-292. PubMed ID: 29240904
    [No Abstract]   [Full Text] [Related]  

  • 9. A multicenter retrospective analysis of sequential treatment of abiraterone acetate followed by docetaxel in Japanese patients with metastatic castration-resistant prostate cancer.
    Ueda Y; Matsubara N; Takizawa I; Nishiyama T; Tabata K; Satoh T; Kamiya N; Suzuki H; Kawahara T; Uemura H
    Jpn J Clin Oncol; 2015 Aug; 45(8):774-9. PubMed ID: 25981621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Author's Reply to Srinivas: "Modeling the Relationship Between Exposure to Abiraterone and Prostate-Specific Antigen Dynamics in Patients with Metastatic Castration-Resistant Prostate Cancer".
    Xu S; De Porre P
    Clin Pharmacokinet; 2017 Feb; 56(2):213-214. PubMed ID: 27815867
    [No Abstract]   [Full Text] [Related]  

  • 11. Re: Redirecting Abiraterone Metabolism to Fine-Tune Prostate Cancer Anti-Androgen Therapy.
    Taneja SS
    J Urol; 2016 Nov; 196(5):1447. PubMed ID: 27751453
    [No Abstract]   [Full Text] [Related]  

  • 12. Food effects on abiraterone pharmacokinetics in healthy subjects and patients with metastatic castration-resistant prostate cancer.
    Chi KN; Spratlin J; Kollmannsberger C; North S; Pankras C; Gonzalez M; Bernard A; Stieltjes H; Peng L; Jiao J; Acharya M; Kheoh T; Griffin TW; Yu MK; Chien C; Tran NP
    J Clin Pharmacol; 2015 Dec; 55(12):1406-14. PubMed ID: 26096139
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Re: Prostate-Specific Antigen Decline after 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-Resistant Prostate Cancer.
    Taneja SS
    J Urol; 2016 Jul; 196(1):103. PubMed ID: 27321503
    [No Abstract]   [Full Text] [Related]  

  • 14. Re: Pasquale Rescigno, David Lorente, Diletta Bianchini, et al. Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer. Eur Urol 2016;70:724-31.
    Conteduca V; Lolli C; De Giorgi U
    Eur Urol; 2016 Dec; 70(6):e168-e169. PubMed ID: 27255584
    [No Abstract]   [Full Text] [Related]  

  • 15. Comment on: "Modeling the Relationship between Exposure to Abiraterone and Prostate-Specific Antigen Dynamics in Patients with Metastatic Castration-Resistant Prostate Cancer".
    Srinivas NR
    Clin Pharmacokinet; 2017 Feb; 56(2):211-212. PubMed ID: 27815866
    [No Abstract]   [Full Text] [Related]  

  • 16. Abiraterone or Docetaxel Plus Androgen Deprivation in Hormone-Sensitive Prostate Cancer: More Questions Than Answers.
    Aggarwal R
    Eur Urol; 2018 Jun; 73(6):845-846. PubMed ID: 29128209
    [No Abstract]   [Full Text] [Related]  

  • 17. Study of cases of abiraterone discontinuation due to toxicity in pre-chemotherapy after 1 year's experience.
    Ramudo-Cela L; Balea-Filgueiras J; Vizoso-Hermida JR; Martín-Herranz I
    J Oncol Pharm Pract; 2017 Dec; 23(8):615-619. PubMed ID: 27753628
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the possible interference of abiraterone therapy on testosterone immunoassay.
    Dittadi R; Polesello V; Zivi A; Carraro P
    Clin Chem Lab Med; 2019 Sep; 57(10):e253-e254. PubMed ID: 30875318
    [No Abstract]   [Full Text] [Related]  

  • 19. Reply to Vincenza Conteduca, Cristian Lolli, and Ugo De Giorgi's Letter to the Editor re: Pasquale Rescigno, David Lorente, Diletta Bianchini, et al. Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer. Eur Urol 2016;70:724-31.
    Rescigno P; de Bono JS
    Eur Urol; 2016 Dec; 70(6):e170-e171. PubMed ID: 27240941
    [No Abstract]   [Full Text] [Related]  

  • 20. Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial.
    Sternberg CN; Castellano D; Daugaard G; Géczi L; Hotte SJ; Mainwaring PN; Saad F; Souza C; Tay MH; Garrido JM; Galli L; Londhe A; De Porre P; Goon B; Lee E; McGowan T; Naini V; Todd MB; Molina A; George DJ;
    Lancet Oncol; 2014 Oct; 15(11):1263-8. PubMed ID: 25242048
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.